TG Therapeutics
TG Therapeutics is a commercial-stage biopharmaceutical company that develops and markets BRIUMVI (ublituximab-xiiy), a glycoengineered anti-CD20 monoclonal antibody FDA-approved for relapsing multiple sclerosis, with a pipeline spanning subcutaneous formulations and allogeneic CAR-T therapies for B-cell mediated diseases.
- Company typePublic
- Founded2012
- HeadquartersNew York, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What TG Therapeutics does
TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company headquartered in Morrisville, North Carolina, focused on developing therapeutics for B-cell mediated diseases, with current commercial emphasis on relapsing forms of multiple sclerosis. The company's lead and only marketed product is BRIUMVI (ublituximab-xiiy), an FDA-approved (January 2023) glycoengineered anti-CD20 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity (ADCC) via removal of fucose sugar residues. BRIUMVI is administered as an intravenous infusion every six months after initial dosing and generated $594.1 million in US net product revenue in 2025 (92% YoY growth), with over 25,000 patients treated globally.
The company's pipeline leverages two distinct technology platforms: the glycoengineered anti-CD20 antibody platform (currently marketed as IV BRIUMVI, plus a subcutaneous formulation in Phase 3 with self-administration potential) and an allogeneic CAR-T platform centered on azercabtagene zapreleucel (azer-cel), a CD19-directed off-the-shelf cell therapy in Phase 1 for progressive MS and other autoimmune conditions, licensed from Precision BioSciences. Clinical differentiation is supported by a 56.7% reduction in annualized relapse rate versus teriflunomide, a 0.020 annualized relapse rate at Year 5, and 92% of patients progression-free at Year 5.
TG Therapeutics monetizes BRIUMVI through a direct US sales force targeting neurologists and MS treatment centers, with prescription pricing negotiated bilaterally through insurance carriers, PBMs, and healthcare systems rather than publicly listed. International commercialization is executed via a partnership with Neuraxpharm covering the EU, UK, Switzerland, Australia, Kuwait, and UAE. Secondary revenue derives from licensing and milestone payments tied to the azer-cel program. The company has reached profitability with $19.8M in Q1 2026 net income and EPS of $2.87, supported by a $750M senior secured credit facility (expandable to $1B) from Blue Owl Capital secured in March 2026 that provides non-dilutive growth capital alongside an expanded $300M share repurchase authorization.
TG Therapeutics firmographics
Firmographics- Name
- TG Therapeutics
- Legal name
- TG Therapeutics, Inc.
- Website
- https://tgtherapeutics.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- TG Therapeutics is a commercial-stage biopharmaceutical company that develops and markets BRIUMVI (ublituximab-xiiy), a glycoengineered anti-CD20 monoclonal antibody FDA-approved for relapsing multiple sclerosis, with a pipeline spanning subcutaneous formulations and allogeneic CAR-T therapies for B-cell mediated diseases.
- Ownership category
- akta.pro rank
TG Therapeutics industry classification
Industry- Product category
- Multiple Sclerosis Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)
Keywords
Where TG Therapeutics is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TG Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- BRIUMVI Product Sales: Commercial revenue from sales of FDA-approved BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis. Revenue has grown from $89 million in 2023 to $594 million in 2025 (U.S. net product revenue), with 2026 guidance of $885-900 million.
- Licensing and Milestone Payments: Revenue from licensing agreements including milestone payments from Precision BioSciences for azer-cel development progress ($7.5 million milestone received in March 2026), with up to $288 million in additional milestones available under the agreement.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
TG Therapeutics product offering
Product offeringCore offering
TG Therapeutics develops and commercializes therapeutics for B-cell mediated diseases, with its flagship commercial product BRIUMVI (ublituximab-xiiy) — a glycoengineered anti-CD20 monoclonal antibody FDA-approved for relapsing forms of multiple sclerosis in adults. The pipeline expands on this platform with a subcutaneous ublituximab formulation in Phase 3 (designed for at-home self-administration) and azercabtagene zapreleucel (azer-cel), an investigational CD19-directed allogeneic CAR-T cell therapy for progressive MS and other autoimmune conditions.
Product overview
TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell diseases, primarily multiple sclerosis. The company markets BRIUMVI (ublituximab-xiiy), an FDA-approved glycoengineered anti-CD20 monoclonal antibody delivered via IV infusion for relapsing forms of MS. The pipeline includes a subcutaneous formulation of ublituximab in Phase 3 development for at-home self-administration, and azercabtagene zapreleucel (azer-cel), a CD19-directed allogeneic CAR-T cell therapy in Phase 1 for progressive MS and other autoimmune conditions.
Differentiator
Problem solved
Functional benefit
Brands
- BRIUMVI: FDA-approved brand name for ublituximab-xiiy, used for treatment of relapsing forms of multiple sclerosis
Products and services
- BRIUMVI (ublituximab-xiiy) FDA-approved glycoengineered anti-CD20 monoclonal antibody for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Administered via intravenous infusion (typically every six months after initial dosing). Sold to neurologists and MS treatment centers across the United States and through Neuraxpharm internationally.
- Subcutaneous Ublituximab Subcutaneous formulation of ublituximab being evaluated in Phase 3 clinical trials for adults with relapsing multiple sclerosis. Designed for self-administration via subcutaneous injection (every 8 or 12 weeks), offering an at-home treatment option as an alternative to IV infusion.
- Azercabtagene zapreleucel (azer-cel) CD19-directed allogeneic CAR-T cell therapy being developed for B-cell mediated autoimmune conditions including progressive multiple sclerosis. Uses healthy donor T cells modified with proprietary gene-editing technology to express CD19-directed CAR while minimizing graft-versus-host disease (GvHD) risk, enabling off-the-shelf availability.
Quantifiable outcome
- 56.7% reduction in annualized relapse rate compared to teriflunomide in treatment-naive patients
- +4 more outcomes
Companies that use TG Therapeutics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
TG Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
TG Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Precision BioSciencescoreTG Therapeutics holds exclusive worldwide rights to develop and commercialize azer-cel (azercabtagene zapreleucel) in autoimmune diseases through licensing agreement with Precision BioSciences. TG paid $7.5 million milestone for Phase 1 trial progress in progressive MS, with up to $288 million in additional milestones plus royalties available.
- NeuraxpharmcoreCollaboration with Neuraxpharm for European and international commercialization of BRIUMVI. The partnership expanded commercialization across European Union, United Kingdom, Switzerland, Australia, Kuwait, and United Arab Emirates following initial European regulatory approvals.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
TG Therapeutics competitors and assessment
Company assessmentDirect peers
- Sanofi: Markets teriflunomide (Aubagio), the active comparator used in BRIUMVI's pivotal ULTIMATE I & II trials. Competes in the same MS treatment paradigm as TG Therapeutics.
- Genentech (Roche): Maker of Ocrevus (ocrelizumab), the leading anti-CD20 monoclonal antibody for relapsing MS and the primary head-to-head competitor to BRIUMVI. Direct product overlap, same patient population, similar mechanism of action.
- Novartis: Markets Kesimpta (ofatumumab), a subcutaneous anti-CD20 monoclonal antibody for relapsing MS. Competes head-to-head with BRIUMVI on anti-CD20 mechanism with the convenience advantage of self-administered subcutaneous injection.
- EMD Serono (Merck KGaA): Markets Mavenclad (cladribine) for relapsing MS, an oral disease-modifying therapy competing for the same high-efficacy patient segment as BRIUMVI. Direct commercial overlap in the relapsing MS market.
- Bristol Myers Squibb: Markets Zeposia (ozanimod) for relapsing MS, an oral S1P receptor modulator. Direct competitor targeting the same relapsing MS patient population with a differentiated oral mechanism.
Emerging players
- Allogene Therapeutics: Allogeneic CAR-T developer with pipeline programs targeting autoimmune diseases. Competes in the same allogeneic CAR-T autoimmune space as TG's azer-cel.
- CRISPR Therapeutics: Developing allogeneic CAR-T cell therapies for autoimmune diseases, directly overlapping with TG's azer-cel program in progressive MS and broader B-cell mediated autoimmune indications.
- Cabaletta Bio: Clinical-stage biotech developing CAR-T cell therapies (e.g., CABA-201) for autoimmune diseases including lupus and other B-cell mediated conditions. Overlapping target indications with TG's azer-cel program.
Broad incumbents
- Biogen: Long-established MS franchise with TYSABRI, AVONEX, PLEGRIDY, and VUMERITY serving the same relapsing MS patient population as BRIUMVI. Major incumbent in MS treatment with broad portfolio and deep neurologist relationships.
Others
- Precision BioSciences: Licensor of azer-cel technology to TG Therapeutics. Partner with material economic interest in azer-cel milestones (up to $288M plus royalties) and recent equity investment from TG.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
TG Therapeutics social profiles
Digital presenceTG Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
TG Therapeutics leadership team
Management profileNumber of profiles
Profiles6 records
TG Therapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TG Therapeutics M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TG Therapeutics
What does TG Therapeutics do?
TG Therapeutics develops and commercializes therapeutics for B-cell mediated diseases, with its flagship commercial product BRIUMVI (ublituximab-xiiy) — a glycoengineered anti-CD20 monoclonal antibody FDA-approved for relapsing forms of multiple sclerosis in adults. The pipeline expands on this platform with a subcutaneous ublituximab formulation in Phase 3 (designed for at-home self-administration) and azercabtagene zapreleucel (azer-cel), an investigational CD19-directed allogeneic CAR-T cell therapy for progressive MS and other autoimmune conditions.
Is TG Therapeutics a public or private company?
TG Therapeutics is a public company. It is classified as public and is currently operating.
When was TG Therapeutics founded?
TG Therapeutics was founded in 2012. It employs 501 to 1,000 people.
Where is TG Therapeutics based?
TG Therapeutics is headquartered in New York, United States, in the North America region.
How does TG Therapeutics make money?
Two revenue lines are on record. BRIUMVI Product Sales are the primary driver. The others are licensing and Milestone Payments.
Who are TG Therapeutics's main competitors?
Direct peers on record are Sanofi, Genentech (Roche), Novartis, EMD Serono (Merck KGaA) and Bristol Myers Squibb. Emerging players are Allogene Therapeutics, CRISPR Therapeutics and Cabaletta Bio. Biogen is listed as a broad incumbent. Precision BioSciences is listed as an others.
Does TG Therapeutics have an API?
No public API is recorded for TG Therapeutics.
What industry is TG Therapeutics in?
TG Therapeutics's product category is Multiple Sclerosis Therapeutics. Its primary akta.pro industry code is HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 325414 and its SIC code is 2836.